-
Je něco špatně v tomto záznamu ?
Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases
RH. Kobayashi, J. Litzman, S. Rizvi, H. Kreuwel, S. Hoeller, S. Gupta
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
34986666
DOI
10.2217/imt-2021-0313
Knihovny.cz E-zdroje
- MeSH
- injekce subkutánní MeSH
- intravenózní imunoglobuliny aplikace a dávkování imunologie terapeutické užití MeSH
- lidé MeSH
- pasivní imunizace metody MeSH
- subkutánní infuze MeSH
- syndromy imunologické nedostatečnosti farmakoterapie imunologie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Most primary immunodeficiency diseases, and select secondary immunodeficiency diseases, are treated with immunoglobulin (IG) therapy, administered intravenously or subcutaneously (SCIG). The first instance of IG replacement for primary immunodeficiency disease was a 16.5% formulation administered subcutaneously in 1952. While most SCIG products are now a 10 or 20% concentration, this review will focus on SCIG 16.5% products with a historical overview of development, including the early pioneers who initiated and refined IG replacement therapy, as well as key characteristics, manufacturing and clinical studies. In determining an appropriate IG regimen, one must consider specific patient needs, characteristics and preferences. There are advantages to SCIG, such as stable serum immunoglobulin G levels, high tolerability and the flexibility of self-administered home treatment.
Division of Basic and Clinical Immunology University of California Irvine CA USA
Octapharma Pharm ProduduktionsgesmbH Vienna Austria
University of California School of Medicine Los Angeles CA USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22010860
- 003
- CZ-PrNML
- 005
- 20220506130847.0
- 007
- ta
- 008
- 220425s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2217/imt-2021-0313 $2 doi
- 035 __
- $a (PubMed)34986666
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kobayashi, Roger H $u University of California, School of Medicine, Los Angeles, CA, USA $1 https://orcid.org/0000000235109861
- 245 10
- $a Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases / $c RH. Kobayashi, J. Litzman, S. Rizvi, H. Kreuwel, S. Hoeller, S. Gupta
- 520 9_
- $a Most primary immunodeficiency diseases, and select secondary immunodeficiency diseases, are treated with immunoglobulin (IG) therapy, administered intravenously or subcutaneously (SCIG). The first instance of IG replacement for primary immunodeficiency disease was a 16.5% formulation administered subcutaneously in 1952. While most SCIG products are now a 10 or 20% concentration, this review will focus on SCIG 16.5% products with a historical overview of development, including the early pioneers who initiated and refined IG replacement therapy, as well as key characteristics, manufacturing and clinical studies. In determining an appropriate IG regimen, one must consider specific patient needs, characteristics and preferences. There are advantages to SCIG, such as stable serum immunoglobulin G levels, high tolerability and the flexibility of self-administered home treatment.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a pasivní imunizace $x metody $7 D007116
- 650 _2
- $a intravenózní imunoglobuliny $x aplikace a dávkování $x imunologie $x terapeutické užití $7 D016756
- 650 _2
- $a syndromy imunologické nedostatečnosti $x farmakoterapie $x imunologie $7 D007153
- 650 _2
- $a subkutánní infuze $7 D055104
- 650 _2
- $a injekce subkutánní $7 D007279
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Litzman, Jiří $u Department of Clinical Immunology & Allergology, St. Anne's University in Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Rizvi, Syed $u Octapharma AG, Paramus, NJ, USA
- 700 1_
- $a Kreuwel, Huub $u Octapharma AG, Paramus, NJ, USA
- 700 1_
- $a Hoeller, Sonja $u Octapharma Pharm. ProduduktionsgesmbH, Vienna, Austria
- 700 1_
- $a Gupta, Sudhir $u Division of Basic & Clinical Immunology, University of California, Irvine, CA, USA
- 773 0_
- $w MED00175821 $t Immunotherapy $x 1750-7448 $g Roč. 14, č. 4 (2022), s. 259-270
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34986666 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130839 $b ABA008
- 999 __
- $a ok $b bmc $g 1788799 $s 1162058
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 14 $c 4 $d 259-270 $e 20220106 $i 1750-7448 $m Immunotherapy $n Immunotherapy $x MED00175821
- LZP __
- $a Pubmed-20220425
